乳腺癌化进展

1、张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454张忠清张忠清 乳腺癌当前流行趋势分析乳腺癌当前流行趋势分析 中国肿瘤中国肿瘤 2000 9 2000 9（1010）：）：454454 dr. ann thor dr. ann thorthe 2nd international breast cancer international research group conferen

2、cethe 2nd international breast cancer international research group conference dr. ann thor dr. ann thorthe 2nd international breast cancer international research group conferencethe 2nd international breast cancer international research group conference dr. ann thor dr. ann thorthe 2nd international

3、 breast cancer international research group conferencethe 2nd international breast cancer international research group conference 江泽飞江泽飞 紫杉类药物在乳腺癌化疗中的地位和临床研究进展紫杉类药物在乳腺癌化疗中的地位和临床研究进展 中国医学论坛报网络版中国医学论坛报网络版866866期期江泽飞江泽飞 紫杉类药物在乳腺癌化疗中的地位和临床研究进展紫杉类药物在乳腺癌化疗中的地位和临床研究进展 中国医学论坛报网络版中国医学论坛报网络版866866期期bishop jf.

4、 initial paclitaxel improves outcome compared bishop jf. initial paclitaxel improves outcome compared with cmfp combination chemotherapy as front-line therapy with cmfp combination chemotherapy as front-line therapy in untreated metastatic breast cancer. in untreated metastatic breast cancer. j j cl

5、inclin oncoloncol. 1999 aug;17(8):2355. 1999 aug;17(8):2355bishop jf. initial paclitaxel improves outcome compared bishop jf. initial paclitaxel improves outcome compared with cmfp combination chemotherapy as front-line therapy with cmfp combination chemotherapy as front-line therapy in untreated me

6、tastatic breast cancer. in untreated metastatic breast cancer. j j clinclin oncoloncol. 1999 aug;17(8):2355. 1999 aug;17(8):2355bishop jf. initial paclitaxel improves outcome compared bishop jf. initial paclitaxel improves outcome compared with cmfp combination chemotherapy as front-line therapy wit

7、h cmfp combination chemotherapy as front-line therapy in untreated metastatic breast cancer. in untreated metastatic breast cancer. j j clinclin oncoloncol. 1999 aug;17(8):2355. 1999 aug;17(8):2355bishop jf. initial paclitaxel improves outcome compared bishop jf. initial paclitaxel improves outcome

8、compared with cmfp combination chemotherapy as front-line therapy with cmfp combination chemotherapy as front-line therapy in untreated metastatic breast cancer. in untreated metastatic breast cancer. j j clinclin oncoloncol. 1999 aug;17(8):2355. 1999 aug;17(8):2355bishop jf. initial paclitaxel impr

9、oves outcome compared bishop jf. initial paclitaxel improves outcome compared with cmfp combination chemotherapy as front-line therapy with cmfp combination chemotherapy as front-line therapy in untreated metastatic breast cancer. in untreated metastatic breast cancer. j j clinclin oncoloncol. 1999

10、aug;17(8):2355. 1999 aug;17(8):2355bishop jf. initial paclitaxel improves outcome compared bishop jf. initial paclitaxel improves outcome compared with cmfp combination chemotherapy as front-line therapy with cmfp combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

11、in untreated metastatic breast cancer. j j clinclin oncoloncol. 1999 aug;17(8):2355. 1999 aug;17(8):2355stocklerstocklerthe 2nd international breast the 2nd international breast cancerinternationalcancerinternational research group conference research group conferencesledge gw. phase iii trial of sl

12、edge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combination the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an cancer: an intergr

13、oupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 2003 feb 15;21(4):588 sledge gw. phase iii trial of sledge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combination the combination of doxorubicin and paclitaxel as front-li

14、ne chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 2003 feb 15;21(4):588 0%0%5%5%10%10%15%15%20%20%25%25%30%30%35

15、%35%40%40%45%45%50%50%a at ta+ta+tcr+prcr+prsledge gw. phase iii trial of sledge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combination the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as

16、 front-line chemotherapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 2003 feb 15;21(4):588 0 01 12 23 34 45 56 67 78 8a at ta+ta+tttf(月)ttf(月)sledge gw. phase iii trial of sledge gw. phase iii trial of

17、 doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combination the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193)

18、. trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 2003 feb 15;21(4):588 171717.517.5181818.518.5191919.519.5202020.520.5212121.521.5222222.522.5a at ta+ta+tms(月)ms(月)sledge gw. phase iii trial of sledge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the co

19、mbination the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):

20、588. 2003 feb 15;21(4):588 sledge gw. phase iii trial of sledge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combination the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemo

21、therapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 2003 feb 15;21(4):588 sledge gw. phase iii trial of sledge gw. phase iii trial of doxorubicin,paclitaxel,anddoxorubicin,paclitaxel,and the combinatio

22、n the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an cancer: an intergroupintergroup trial (e1193). trial (e1193). j j clinclin oncoloncol. 2003 feb 15;21(4):588. 200

23、3 feb 15;21(4):588 dr. george sledgedr. george sledgethe 2nd international breast the 2nd international breast cancerinternationalcancerinternational research group conference research group conferencedr. george sledgedr. george sledgethe 2nd international breast the 2nd international breast canceri

24、nternationalcancerinternational research group conference research group conferencechan s. prospective randomized trial of chan s. prospective randomized trial of docetaxeldocetaxel versus doxorubicin in patients with metastatic breast versus doxorubicin in patients with metastatic breast cancer. th

25、e 303 study group. cancer. the 303 study group. j j clinclin oncoloncol. 1999 aug;17(8):2341 . 1999 aug;17(8):2341 chan s. prospective randomized trial of chan s. prospective randomized trial of docetaxeldocetaxel versus doxorubicin in patients with metastatic breast versus doxorubicin in patients w

26、ith metastatic breast cancer. the 303 study group. cancer. the 303 study group. j j clinclin oncoloncol. 1999 aug;17(8):2341 . 1999 aug;17(8):2341 chan s. prospective randomized trial of chan s. prospective randomized trial of docetaxeldocetaxel versus doxorubicin in patients with metastatic breast

27、versus doxorubicin in patients with metastatic breast cancer. the 303 study group. cancer. the 303 study group. j j clinclin oncoloncol. 1999 aug;17(8):2341 . 1999 aug;17(8):2341 nabholtznabholtz jm. prospective randomized trial of jm. prospective randomized trial of docetaxeldocetaxel versus mitomy

28、cin plus versus mitomycin plus vinblastinevinblastine in patients with metastatic breast cancer progressing despite in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group.previous anthracycline-containing chemotherapy. 304 study

29、group. j j clinclin oncoloncol. 1999 may;17(5):1413-24 . 1999 may;17(5):1413-24 nabholtznabholtz jm. prospective randomized trial of jm. prospective randomized trial of docetaxeldocetaxel versus mitomycin plus versus mitomycin plus vinblastinevinblastine in patients with metastatic breast cancer pro

30、gressing despite in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group.previous anthracycline-containing chemotherapy. 304 study group. j j clinclin oncoloncol. 1999 may;17(5):1413-24 . 1999 may;17(5):1413-24 0.00%0.00%5.00%5.00

31、%10.00%10.00%15.00%15.00%20.00%20.00%25.00%25.00%30.00%30.00%35.00%35.00%多西紫杉醇多西紫杉醇mvmv总有效率总有效率内脏转移内脏转移肝转移肝转移蒽环类耐药蒽环类耐药nabholtznabholtz jm. prospective randomized trial of jm. prospective randomized trial of docetaxeldocetaxel versus mitomycin plus versus mitomycin plus vinblastinevinblastine in pat

32、ients with metastatic breast cancer progressing despite in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group.previous anthracycline-containing chemotherapy. 304 study group. j j clinclin oncoloncol. 1999 may;17(5):1413-24 . 199

33、9 may;17(5):1413-24 nabholtznabholtz jm. prospective randomized trial of jm. prospective randomized trial of docetaxeldocetaxel versus mitomycin plus versus mitomycin plus vinblastinevinblastine in patients with metastatic breast cancer progressing despite in patients with metastatic breast cancer p

34、rogressing despite previous anthracycline-containing chemotherapy. 304 study group.previous anthracycline-containing chemotherapy. 304 study group. j j clinclin oncoloncol. 1999 may;17(5):1413-24 . 1999 may;17(5):1413-24 nabholtznabholtz jm. prospective randomized trial of jm. prospective randomized trial of docetaxeldocetaxel versus mitom